MT1-MMP in breast cancer: Induction of VEGF-C correlates with metastasis and poor prognosis

Cancer Cell International

Volumn 13, Issue 1, 2013, Pages

  Yao, Guangyu ^a   He, Ping ^b   Chen, Lujia ^a   Hu, Xiaolei ^a   Gu, Fan ^a   Ye, Changsheng ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Lymphangiogenesis; Membrane type matrix 1 metalloproteinases; Metastasis; Vascular endothelial growth factor C

Indexed keywords

MATRIX METALLOPROTEINASE 14; VASCULOTROPIN C;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER PROGNOSIS; CANCER STAGING; CARCINOMA CELL; CELL INVASION; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; LYMPH VESSEL; LYMPHANGIOGENESIS; MAJOR CLINICAL STUDY; METASTASIS; OVERALL SURVIVAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84885361721     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-13-98     Document Type: Article

References (62)

1. Genis L, Galvez BG, Gonzalo P, Arroyo AG. MT1-MMP: universal or particular player in angiogenesis?. Cancer Metastasis Rev 2006, 25(1):77-86. 10.1007/s10555-006-7891-z, 16680574.
2. Itoh Y, Nagase H. Matrix metalloproteinases in cancer. Essays Biochem 2002, 38:21-36.
3. Zucker S, Pei D, Cao J, Lopez-Otin C. Membrane type-matrix metalloproteinases (MT-MMP). Curr Topics Dev Biol 2003, 54:1-74.
4. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994, 370(6484):61-65. 10.1038/370061a0, 8015608.
5. Stetler-Stevenson WG, Liotta LA, Kleiner DE. Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. Faseb J 1993, 7(15):1434-1441.
6. Sato H, Takino T, Miyamori H. Roles of membrane-type matrix metalloproteinase-1 in tumor invasion and metastasis. Cancer Sci 2005, 96(4):212-217. 10.1111/j.1349-7006.2005.00039.x, 15819718.
7. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K, Detmar M. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001, 7(2):192-198. 10.1038/84643, 11175850.
8. Akagi K, Ikeda Y, Miyazaki M, Abe T, Kinoshita J, Maehara Y, Sugimachi K. Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues. British J Cancer 2000, 83(7):887-891.
9. Hotary K, Li XY, Allen E, Stevens SL, Weiss SJ. A cancer cell metalloprotease triad regulates the basement membrane transmigration program. Genes Dev 2006, 20(19):2673-2686. 10.1101/gad.1451806, 1578694, 16983145.
10. Gilles C, Polette M, Coraux C, Tournier JM, Meneguzzi G, Munaut C, Volders L, Rousselle P, Birembaut P, Foidart JM. Contribution of MT1-MMP and of human laminin-5 gamma2 chain degradation to mammary epithelial cell migration. J Cell Sci 2001, 114(Pt 16):2967-2976. 2966877, 11686300.
11. Xu J, Rodriguez D, Petitclerc E, Kim JJ, Hangai M, Moon YS, Davis GE, Brooks PC. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol 2001, 154(5):1069-1079. 10.1083/jcb.200103111, 2196184, 11535623.
12. Wolf K, Wu YI, Liu Y, Geiger J, Tam E, Overall C, Stack MS, Friedl P. Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat Cell Biol 2007, 9(8):893-904. 10.1038/ncb1616, 17618273.
13. Kajita M, Itoh Y, Chiba T, Mori H, Okada A, Kinoh H, Seiki M. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol 2001, 153(5):893-904. 10.1083/jcb.153.5.893, 2174329, 11381077.
14. Suenaga N, Mori H, Itoh Y, Seiki M. CD44 binding through the hemopexin-like domain is critical for its shedding by membrane-type 1 matrix metalloproteinase. Oncogene 2005, 24(5):859-868. 10.1038/sj.onc.1208258, 15558018.
15. Deryugina EI, Bourdon MA, Jungwirth K, Smith JW, Strongin AY. Functional activation of integrin alpha V beta 3 in tumor cells expressing membrane-type 1 matrix metalloproteinase. Int J Cancer 2000, 86(1):15-23. 10.1002/(SICI)1097-0215(20000401)86:1<15::AID-IJC3>3.0.CO;2-B, 10728589.
16. Deryugina EI, Ratnikov BI, Postnova TI, Rozanov DV, Strongin AY. Processing of integrin alpha(v) subunit by membrane type 1 matrix metalloproteinase stimulates migration of breast carcinoma cells on vitronectin and enhances tyrosine phosphorylation of focal adhesion kinase. J Biol Chem 2002, 277(12):9749-9756. 10.1074/jbc.M110269200, 11724803.
17. Sodek KL, Ringuette MJ, Brown TJ. MT1-MMP is the critical determinant of matrix degradation and invasion by ovarian cancer cells. British J Cancer 2007, 97(3):358-367.
18. Bonnomet A, Polette M, Strumane K, Gilles C, Dalstein V, Kileztky C, Berx G, van Roy F, Birembaut P, Nawrocki-Raby B. The E-cadherin-repressed hNanos1 gene induces tumor cell invasion by upregulating MT1-MMP expression. Oncogene 2008, 27(26):3692-3699. 10.1038/sj.onc.1211035, 18223680.
19. Chernov AV, Sounni NE, Remacle AG, Strongin AY. Epigenetic control of the invasion-promoting MT1-MMP/MMP-2/TIMP-2 axis in cancer cells. J Biol Chem 2009, 284(19):12727-12734. 10.1074/jbc.M900273200, 2676002, 19286653.
20. Achen MG, Stacker SA. Molecular control of lymphatic metastasis. Ann NY Acad Sci 2008, 1131:225-234. 10.1196/annals.1413.020, 18519975.
21. Su JL, Yang PC, Shih JY, Yang CY, Wei LH, Hsieh CY, Chou CH, Jeng YM, Wang MY, Chang KJ, et al. The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer cell 2006, 9(3):209-223. 10.1016/j.ccr.2006.02.018, 16530705.
22. Yu M, Tang Z, Alousi S, Berk RS, Miller F, Kosir MA. Expression patterns of lymphangiogenic and angiogenic factors in a model of breast ductal carcinoma in situ. Am J Surg 2007, 194(5):594-599. 10.1016/j.amjsurg.2007.08.007, 17936419.
23. Bock JM, Sinclair LL, Bedford NS, Jackson RE, Lee JH, Trask DK. Modulation of cellular invasion by VEGF-C expression in squamous cell carcinoma of the head and neck. Arch Otolaryngolog Head Neck Surg 2008, 134(4):355-362.
24. Donnem T, Al-Saad S, Al-Shibli K, Delghandi MP, Persson M, Nilsen MN, Busund LT, Bremnes RM. Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer. Clin Cancer Res 2007, 13(22 Pt 1):6649-6657.
25. Donnem T, Al-Shibli K, Al-Saad S, Busund LT, Bremnes RM. Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival. J Thorac Oncol 2009, 4(5):578-585. 10.1097/JTO.0b013e31819f2e38, 19318994.
26. Simiantonaki N, Jayasinghe C, Michel-Schmidt R, Peters K, Hermanns MI, Kirkpatrick CJ. Hypoxia-induced epithelial VEGF-C/VEGFR-3 upregulation in carcinoma cell lines. Int J Oncol 2008, 32(3):585-592.
27. Witte D, Thomas A, Ali N, Carlson N, Younes M. Expression of the vascular endothelial growth factor receptor-3 (VEGFR-3) and its ligand VEGF-C in human colorectal adenocarcinoma. Anticancer Res 2002, 22(3):1463-1466.
28. Simiantonaki N, Taxeidis M, Jayasinghe C, Kirkpatrick CJ. Epithelial expression of VEGF receptors in colorectal carcinomas and their relationship to metastatic status. Anticancer Res 2007, 27(5A):3245-3250.
29. Neuchrist C, Erovic BM, Handisurya A, Fischer MB, Steiner GE, Hollemann D, Gedlicka C, Saaristo A, Burian M. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck. Head Neck 2003, 25(6):464-474. 10.1002/hed.10235, 12784238.
30. Warburton G, Nikitakis NG, Roberson P, Marinos NJ, Wu T, Sauk JJ, Ord RA, Wahl SM. Histopathological and lymphangiogenic parameters in relation to lymph node metastasis in early stage oral squamous cell carcinoma. J Oral Maxillofac Surg 2007, 65(3):475-484. 10.1016/j.joms.2005.12.074, 17307596.
31. Kaushal V, Mukunyadzi P, Dennis RA, Siegel ER, Johnson DE, Kohli M. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease. Clin Cancer Res 2005, 11(2 Pt 1):584-593.
32. Ma C, Lin H, Leonard SS, Shi X, Ye J, Luo J. Overexpression of ErbB2 enhances ethanol-stimulated intracellular signaling and invasion of human mammary epithelial and breast cancer cells in vitro. Oncogene 2003, 22(34):5281-5290. 10.1038/sj.onc.1206675, 12917629.
33. Steeg PS. Metastasis suppressors alter the signal transduction of cancer cells. Nature Rev 2003, 3(1):55-63.
34. Kim HJ, Park CI, Park BW, Lee HD, Jung WH. Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast. Yonsei Med J 2006, 47(3):333-342. 10.3349/ymj.2006.47.3.333, 2688152, 16807982.
35. Tetu B, Brisson J, Wang CS, Lapointe H, Beaudry G, Blanchette C, Trudel D. The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis. Breast Cancer Res 2006, 8(3):R28. 10.1186/bcr1503, 1557730, 16776850.
36. Ogura S, Ohdaira T, Hozumi Y, Omoto Y, Nagai H. Metastasis-related factors expressed in pT1 pN0 breast cancer: assessment of recurrence risk. J Surg Oncol 2007, 96(1):46-53. 10.1002/jso.20805, 17385712.
37. Jiang WG, Davies G, Martin TA, Parr C, Watkins G, Mason MD, Mansel RE. Expression of membrane type-1 matrix metalloproteinase, MT1-MMP in human breast cancer and its impact on invasiveness of breast cancer cells. Int J Mol Med 2006, 17(4):583-590.
38. Jones JL, Glynn P, Walker RA. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol 1999, 189(2):161-168. 10.1002/(SICI)1096-9896(199910)189:2<161::AID-PATH406>3.0.CO;2-2, 10547569.
39. Mylona E, Nomikos A, Magkou C, Kamberou M, Papassideri I, Keramopoulos A, Nakopoulou L. The clinicopathological and prognostic significance of membrane type 1 matrix metalloproteinase (MT1-MMP) and MMP-9 according to their localization in invasive breast carcinoma. Histopathology 2007, 50(3):338-347. 10.1111/j.1365-2559.2007.02615.x, 17257129.
40. Ishigaki S, Toi M, Ueno T, Matsumoto H, Muta M, Koike M, Seiki M. Significance of membrane type 1 matrix metalloproteinase expression in breast cancer. Jpn J Cancer Res 1999, 90(5):516-522. 10.1111/j.1349-7006.1999.tb00778.x, 10391091.
41. Teramoto S, Arihiro K, Koseki M, Kataoka T, Asahara T, Ohdan H. Role of vascular endothelial growth factor-C and -D mRNA in breast cancer. Hiroshima J Med Sci 2008, 57(2):73-78.
42. Nakamura Y, Yasuoka H, Tsujimoto M, Yang Q, Tsukiyama A, Imabun S, Nakahara M, Nakao K, Nakamura M, Mori I, et al. Clinicopathological significance of vascular endothelial growth factor-C in breast carcinoma with long-term follow-up. Mod Pathol 2003, 16(4):309-314. 10.1097/01.MP.0000062858.98295.9F, 12692195.
43. Kurebayashi J, Otsuki T, Kunisue H, Mikami Y, Tanaka K, Yamamoto S, Sonoo H. Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. Jpn J Cancer Res 1999, 90(9):977-981. 10.1111/j.1349-7006.1999.tb00844.x, 10551327.
44. Li YS, Kaneko M, Amatya VJ, Takeshima Y, Arihiro K, Inai K. Expression of vascular endothelial growth factor-C and its receptor in invasive micropapillary carcinoma of the breast. Pathol Int 2006, 56(5):256-261. 10.1111/j.1440-1827.2006.01961.x, 16669874.
45. Mohammed RA, Green A, El-Shikh S, Paish EC, Ellis IO, Martin SG. Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis. British J Cancer 2007, 96(7):1092-1100.
46. Kinoshita J, Kitamura K, Kabashima A, Saeki H, Tanaka S, Sugimachi K. Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer. Breast Cancer Res Treat 2001, 66(2):159-164. 10.1023/A:1010692132669, 11437102.
47. Bando H, Weich HA, Horiguchi S, Funata N, Ogawa T, Toi M. The association between vascular endothelial growth factor-C, its corresponding receptor, VEGFR-3, and prognosis in primary breast cancer: a study with 193 cases. Oncol Rep 2006, 15(3):653-659.
48. Nakamura Y, Yasuoka H, Tsujimoto M, Yoshidome K, Nakahara M, Nakao K, Nakamura M, Kakudo K. Nitric oxide in breast cancer: induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis. Clin Cancer Res 2006, 12(4):1201-1207. 10.1158/1078-0432.CCR-05-1269, 16489074.
49. Zhang XH, Huang DP, Guo GL, Chen GR, Zhang HX, Wan L, Chen SY. Coexpression of VEGF-C and COX-2 and its association with lymphangiogenesis in human breast cancer. BMC cancer 2008, 8:4. 10.1186/1471-2407-8-4, 2253544, 18190720.
50. Watanabe O, Kinoshita J, Shimizu T, Imamura H, Hirano A, Okabe T, Aiba M, Ogawa K. Expression of a CD44 variant and VEGF-C and the implications for lymphatic metastasis and long-term prognosis of human breast cancer. J Exp Clin Cancer Res 2005, 24(1):75-82.
51. Schoppmann SF, Fenzl A, Nagy K, Unger S, Bayer G, Geleff S, Gnant M, Horvat R, Jakesz R, Birner P. VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact on lymphangiogenesis and survival. Surgery 2006, 139(6):839-846. 10.1016/j.surg.2005.12.008, 16782443.
52. Gisterek I, Matkowski R, Kozlak J, Dus D, Lacko A, Szelachowska J, Kornafel J. Evaluation of prognostic value of VEGF-C and VEGF-D in breast cancer-10 year's follow-up analysis. Anticancer Res 2007, 27(4C):2797-2802.
53. van der Schaft DW, Pauwels P, Hulsmans S, Zimmermann M, van de Poll-Franse LV, Griffioen AW. Absence of lymphangiogenesis in ductal breast cancer at the primary tumor site. Cancer letters 2007, 254(1):128-136. 10.1016/j.canlet.2007.03.001, 17442484.
54. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410(6824):50-56. 10.1038/35065016, 11242036.
55. Kriehuber E, Breiteneder-Geleff S, Groeger M, Soleiman A, Schoppmann SF, Stingl G, Kerjaschki D, Maurer D. Isolation and characterization of dermal lymphatic and blood endothelial cells reveal stable and functionally specialized cell lineages. J Exp Med 2001, 194(6):797-808. 10.1084/jem.194.6.797, 2195953, 11560995.
56. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature 2005, 438(7070):946-953. 10.1038/nature04480, 16355212.
57. Boardman KC, Swartz MA. Interstitial flow as a guide for lymphangiogenesis. Circulation Res 2003, 92(7):801-808. 10.1161/01.RES.0000065621.69843.49, 12623882.
58. Bauer SM, Bauer RJ, Liu ZJ, Chen H, Goldstein L, Velazquez OC. Vascular endothelial growth factor-C promotes vasculogenesis, angiogenesis, and collagen constriction in three-dimensional collagen gels. J Vasc Surg 2005, 41(4):699-707. 10.1016/j.jvs.2005.01.015, 15874936.
59. Nakamura ES, Koizumi K, Kobayashi M, Saiki I. Inhibition of lymphangiogenesis-related properties of murine lymphatic endothelial cells and lymph node metastasis of lung cancer by the matrix metalloproteinase inhibitor MMI270. Cancer science 2004, 95(1):25-31. 10.1111/j.1349-7006.2004.tb03166.x, 14720323.
60. Choi WW, Lewis MM, Lawson D, Yin-Goen Q, Birdsong GG, Cotsonis GA, Cohen C, Young AN. Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression. Mod Pathol 2005, 18(1):143-152. 10.1038/modpathol.3800253, 15297858.
61. Kahn HJ, Marks A. A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest 2002, 82(9):1255-1257. 10.1097/01.LAB.0000028824.03032.AB, 12218087.
62. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995, 36(2):169-180. 10.1007/BF00666038, 8534865.